Riskpilot← Back to searchSign inGet full accessMedelixir AB
ABBankruptOrg 5569923211Activities of agents involved in the wholesale of other particular products · NACE 4618Est. 20140 employees
Revenue 2024
SEK 0
EBITDA margin
—
Equity ratio
-36.3%
Financial strength
Net profit 2024
—
0 employees
| Revenue | SEK 0 | — |
| EBITDA | — | — |
| Net profit | — | — |
| Total assets | SEK 298K | +0% |
| Equity | SEK -108K | +0% |
| Employees | 0 | — |
Legal name
Medelixir AB
Org number
5569923211
Legal form
Aktiebolag
NACE code
4618 · Activities of agents involved in the wholesale of other particular products
Founded
26 november 2014
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Föremålet för bolagets verksamhet är att bedriva medicinsk utvecklings- och innovationsverksamhet, ny terapi och därmed förenlig verksamhet.
Address
Email
niclas@adlerindustries.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 97 | 48 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −73 | −27 | −33 | — | — |
| Depreciation & amort. | −2 | −6 | −6 | — | — |
| EBIT | −75 | −33 | −39 | 0 | 0 |
| Net financials | — | — | — | — | — |
| Profit before tax | −75 | −33 | −39 | 0 | 0 |
| Tax | −0 | −0 | −0 | — | — |
| Net profit | −75 | −33 | −39 | 0 | — |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 300 | 304 | 298 | 298 | 298 |
| Equity | −36 | −69 | −108 | −108 | −108 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 336 | 374 | 406 | 406 | 406 |
| Total debt | 336 | 374 | 406 | 406 | 406 |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20202024
Equity ratio
-36.3%
This company
38.2%
Market median
-195% vs market
20202024
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20202024
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
3.76×
This company
0.62×
Market median
-506% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
TK Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2022 |
LS Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Medelixir AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tünde Katalin Juhasz | Deputy Chief Executive Officer | 0 companies |
| Laszlo Szekely | Chief Executive Officer | 0 companies |
| Bo Niclas Adler | Chairman | 0 companies |